Elanco Animal Health vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Elanco Animal Health (ELAN)

Q3 202616 Jul – 31 Aug 2026

▲4

Elanco beats Q2, raises guidance, wins FDA nod and expands plant

Q2 beat and raised 2026 guidance Elanco beat second-quarter estimates and raised its full-year 2026 outlook, with revenue up about 10% to $1.37 billion and adjusted EPS of 34 cents. Management lifted revenue, profit and innovation targets, signaling stronger demand for its new pet and farm animal products. Higher expected earnings make the stock more attractive to investors.
This is the core new financial event that directly lifts ELAN's earnings outlook and stock price.
FDA emergency use authorization for CLiK Extra The FDA granted Elanco emergency use authorization for CLiK Extra, a wound spray to prevent new world screwworm in livestock and wildlife. This followed the first U.S. animal case in Texas. The authorization opens a new over-the-counter product line and shows Elanco's ability to respond to emerging animal health threats.
A new regulatory approval creates a fresh revenue opportunity and supports the stock.
Kansas biologics plant expansion completed Elanco finished a $120 million expansion of its Kansas biologics facility, more than quadrupling monoclonal antibody production capacity. The added capacity supports the launch of Befrena for canine allergies and Trutect for parvovirus, with Befrena demand running twice expectations. More supply helps Elanco meet strong demand and grow sales.
This new capacity directly enables higher sales of key new products, supporting future revenue.
Pet anti-aging trend boosts long-term demand The anti-aging trend is spreading to pets, with U.S. pet spending expected to hit a record $165 billion this year. Elanco invested $368 million in pet longevity research last year, positioning it in a growing market. Rising pet owner spending on health and longevity supports demand for Elanco's products over time.
A new market trend that expands the potential customer base and long-term demand for Elanco's pet products.

August 202616 Jul – 31 Aug 2026

▲4

Elanco beats Q2, raises guidance, wins FDA nod and expands plant

Q2 beat and raised 2026 guidance Elanco beat second-quarter estimates and raised its full-year 2026 outlook, with revenue up about 10% to $1.37 billion and adjusted EPS of 34 cents. Management lifted revenue, profit and innovation targets, signaling stronger demand for its new pet and farm animal products. Higher expected earnings make the stock more attractive to investors.
This is the core new financial event that directly lifts ELAN's earnings outlook and stock price.
FDA emergency use authorization for CLiK Extra The FDA granted Elanco emergency use authorization for CLiK Extra, a wound spray to prevent new world screwworm in livestock and wildlife. This followed the first U.S. animal case in Texas. The authorization opens a new over-the-counter product line and shows Elanco's ability to respond to emerging animal health threats.
A new regulatory approval creates a fresh revenue opportunity and supports the stock.
Kansas biologics plant expansion completed Elanco finished a $120 million expansion of its Kansas biologics facility, more than quadrupling monoclonal antibody production capacity. The added capacity supports the launch of Befrena for canine allergies and Trutect for parvovirus, with Befrena demand running twice expectations. More supply helps Elanco meet strong demand and grow sales.
This new capacity directly enables higher sales of key new products, supporting future revenue.
Pet anti-aging trend boosts long-term demand The anti-aging trend is spreading to pets, with U.S. pet spending expected to hit a record $165 billion this year. Elanco invested $368 million in pet longevity research last year, positioning it in a growing market. Rising pet owner spending on health and longevity supports demand for Elanco's products over time.
A new market trend that expands the potential customer base and long-term demand for Elanco's pet products.

Latest16 Jul – 31 Aug 2026

▲4

Elanco beats Q2, raises guidance, wins FDA nod and expands plant

Q2 beat and raised 2026 guidance Elanco beat second-quarter estimates and raised its full-year 2026 outlook, with revenue up about 10% to $1.37 billion and adjusted EPS of 34 cents. Management lifted revenue, profit and innovation targets, signaling stronger demand for its new pet and farm animal products. Higher expected earnings make the stock more attractive to investors.
This is the core new financial event that directly lifts ELAN's earnings outlook and stock price.
FDA emergency use authorization for CLiK Extra The FDA granted Elanco emergency use authorization for CLiK Extra, a wound spray to prevent new world screwworm in livestock and wildlife. This followed the first U.S. animal case in Texas. The authorization opens a new over-the-counter product line and shows Elanco's ability to respond to emerging animal health threats.
A new regulatory approval creates a fresh revenue opportunity and supports the stock.
Kansas biologics plant expansion completed Elanco finished a $120 million expansion of its Kansas biologics facility, more than quadrupling monoclonal antibody production capacity. The added capacity supports the launch of Befrena for canine allergies and Trutect for parvovirus, with Befrena demand running twice expectations. More supply helps Elanco meet strong demand and grow sales.
This new capacity directly enables higher sales of key new products, supporting future revenue.
Pet anti-aging trend boosts long-term demand The anti-aging trend is spreading to pets, with U.S. pet spending expected to hit a record $165 billion this year. Elanco invested $368 million in pet longevity research last year, positioning it in a growing market. Rising pet owner spending on health and longevity supports demand for Elanco's products over time.
A new market trend that expands the potential customer base and long-term demand for Elanco's pet products.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.